CROI 2015 Program and Abstracts

Oral Sessions

Session TD-Z Themed Discussion

Room 6C

115LB Early ART and IPT in HIV-Infected African Adults With High CD4 Count (Temprano Trial) Christine Danel 1 ; Raoul Moh 2 ; Delphine Gabillard 1 ; Anani Badje 4 ; Jerome Le Carrou 1 ; Gerard M. Kouame 4 ; Jean Baptiste Ntakpe 4 ; Hervé Ménan 3 ; Serge Eholie 2 ; Xavier Anglaret 1 On behalf of theTemprano Study Group 1 Inserm, Bordeaux, France; 2 Université Felix Houphouet Boigny, Abidjan, Côte d’Ivoire; 3 CHU de Treichville, Abidjan, Côte d’Ivoire; 4 Programme PACCI, Abidjan, Côte d’Ivoire 116 Antiretroviral Drug Screening Provides Key Insights Into HIV Drug Resistance Iris Chen 1 ; Matthew B. Connor 2 ;William Clarke 1 ; Mark A. Marzinke 1 ;Vanessa Cummings 1 ; Sheldon D. Fields 3 ; Darrell P.Wheeler 4 ; Kenneth H. Mayer 5 ; Beryl A. Koblin 6 ; Susan H. Eshleman 1 1 Johns Hopkins University School of Medicine, Baltimore, MD, US; 2 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3 Florida International University, Miami, FL, US; 4 Loyola University Chicago, Chicago, IL, US; 5 Fenway Health, Boston, MA, US; 6 New York Blood Center, New York, NY, US 117 Untimed Drug Levels and Resistance in Patients Experiencing Low-Level HIV Viremia Alejandro Gonzalez-Serna ; Luke C. Swenson; Adriana Nohpal; BirgitWatson; Kate Auyeung; Julio Montaner; Richard Harrigan BC Centre for Excellence in HIV/AIDS, Vancouver, Canada 118 Pretreatment HIV Drug Resistance Increases Regimen Switch in Sub- Saharan Africa Tamara Sonia Boender 1 ; Bernice M. Hoenderboom 1 ; Kim C. Sigaloff 1 ; Maureen Wellington 2 ; Margaret Siwale 3 ; Cissy M. Kityo 4 ; Alani Sulaimon Akanmu 5 ; Mariette E. Botes 6 ; Tobias F. Rinke deWit 1 On behalf of the PASER Study Group 1 Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 2 Newlands Clinic, Harare, Zimbabwe; 3 Lusaka Trust Hospital, Lusaka, Zambia; 4 Joint Clinical Research Centre, Kampala, Uganda; 5 Lagos University Teaching Hospital, Lagos, Nigeria; 6 Muelmed Hospital, Pretoria, South Africa 119 Impact of NRTI Cross-Resistance on Second-Line PI + NRTI Therapy Outcomes in Africa Nicholas Paton 1 ; Cissy Kityo 2 ; JenniferThompson 5 ; Leonard Bagenda 2 ; James Hakim 6 ; Joep van Oosterhout 4 ; Andrew D. Kambugu 3 ; Anne Hoppe 5 ; SarahWalker 5 On behalf of the EARNESTTrialTeam 1 National University of Singapore, Singapore, Singapore; 2 Joint Clinical Research Centre, Kampala, Uganda; 3 Infectious Diseases Institute, Kampala, Uganda; 4 University of Malawi, Blantyre, Malawi; 5 MRC Clinical Trials Unit at University College London, London, United Kingdom; 6 University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe 120 Fitness Effects of Drug-Resistant Strains Across the United States HIV-1 Transmission Network Joel O. Wertheim 1 ; Alexandra M. Oster 2 ; Neeraja Saduvala 2 ;Walid Heneine 2 ; Jeffery A. Johnson 2 ;WilliamM. Switzer 2 ; Angela L. Hernandez 2 ; H. Irene Hall 2 1 University of California San Diego, San Diego, CA, US; 2 US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US 121 Dolutegravir Resistance Requires Multiple Primary Mutations in HIV-1 Integrase

1:30 pm– 2:30 pm Economic Implications of ART Themed Discussion Leader John Blandford , US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US 1104 The Lifetime Medical Cost Savings From Preventing HIV in the United States Bruce R. Schackman 1 ; John Fleishman 6 ; Amanda Su 2 ; Richard Moore 5 ; RochelleWalensky 2 ; David Paltiel 3 ; MiltonWeinstein 4 ; Kenneth Freedberg 2 ; Kelly Gebo 5 ; Elena Losina 2 1 Weill Cornell Medical College, New York, NY, US; 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3 Yale School of Public Health, New Haven, CT, US; 4 Harvard School of Public Health, Boston, MA, US; 5 Johns Hopkins University School of Medicine, Baltimore, MD, US; 6 Agency for Healthcare Research and Quality, Rockville, MD, US 1119 Survival Benefits Attributable to the Brazilian National ART Policy Paula M. Luz 1 ; Michael P. Girouard 2 ; Beatriz Grinsztejn 1 ; Kenneth Freedberg 2 ;Valdilea Veloso 1 ; Elena Losina 4 ; Claudio Struchiner 1 ; Robert Parker 2 ; David Paltiel 3 ; RochelleWalensky 2 1 Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil; 2 Massachusetts General Hospital, Boston, MA, US; 3 Yale School of Public Health, New Haven, CT, US; 4 Brigham and Women’s Hospital, Boston, MA, US 1110 The Cost-Effectiveness of Early ART Initiation in South Africa: A Quasi- Experiment Jacob Bor 1 ; Ellen Moscoe 2 ; Natsayi Chimbindi 3 ; Kobus Herbst 3 ; Kevindra K. Naidu 3 ; Frank Tanser 3 ; Deenan Pillay 3 ;Till Barnighausen 3 1 Boston University School of Public Health, Boston, MA, US; 2 Harvard School of Public Health, Boston, MA, US; 3 Wellcome Trust Africa Centre for Health and Population Studies, Somkhele, South Africa 1111 Community-Based Strategies to Strengthen the Continuum of HIV Care Are Cost-Effective Jennifer A. Smith 1 ; Monisha Sharma 2 ; Carol Levin 2 ; Jared Baeten 2 ; Heidi van Rooyen 3 ; Connie Celum 2 ;Timothy Hallett 1 ; RuanneV. Barnabas 2 1 Imperial College London, London, United Kingdom; 2 University of Washington, Seattle, WA, US; 3 Human Sciences Research Council, Sweetwaters, South Africa 1114 Global Fund Cost Projections for ImplementingWHO 2013 Guidelines Obinna Onyekwena ; Ade Fakoya; Michael Johnson; Michael Olszak-Olszewski; Mark Dybul The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland Session O-10 Oral Abstracts Room 6C 4:00 pm– 6:15 pm New Antiretroviral Agents, Strategies, and HIV Drug Resistance Moderators Constance Delaugerre , Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France Richard Harrigan , BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada 113LB Tenofovir Alafenamide (TAF) in a Single-Tablet Regimen in Initial HIV-1 Therapy DavidWohl 1 ; Anton Pozniak 2 ; MelanieThompson 3 ; Edwin DeJesus 4 ; Daniel Podzamczer 5 ; Jean-Michel Molina 6 ; Gordon Crofoot 7 ; Christian Callebaut 8 ; Hal Martin 8 ; Scott McCallister 8 1 University of North Carolina, Chapel Hill, NC, US; 2 Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; 3 AIDS Research Consortium of Atlanta, Atlanta, GA, US; 4 Orlando Immunology Center, Orlando, FL, US; 5 Hospital Universitari de Bellvitge, Barcelona, Spain; 6 Hopital Saint Louis, Paris, France; 7 Gordon Crofoot Research, Houston, TX, US; 8 Gilead Sciences, Inc, Foster City, CA, US; 9 Gilead Sciences, Inc, Foster City, CA, US 114LB Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor Carey Hwang 1 ; Dirk Schürmann 2 ; Christian Sobotha 2 ; Heather Sevinsky 1 ; Palanikumar Ravindran 1 ; Hong Xiao 1 ; Neelanjana Ray 1 ; Mark Krystal 3 ; Ira B. Dicker 3 ; Max Lataillade 3 1 Bristol-Myers Squibb, Princeton, NJ, US; 2 Charité Research Organisation GmbH, Berlin, Germany; 3 Bristol-Myers Squibb, Wallingford, CT, US

Wednesday, February 25, 2015 • Oral Sessions

Arne Frantzell; Christos J Petropoulos; Wei Huang Monogram Biosciences, South San Francisco, CA, US

14

CROI 2015